A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.

被引：1

作者：

Townsend, Amanda Rose

Hardingham, Jennifer

Tebbutt, Niall C.

Karapetis, Christos Stelios

Singhal, Nimit

Joshi, Rohit

Yeend, Sue

Cooper, Pamela

Dorward, Hilary

Price, Timothy Jay

机构：

[1] Univ Adelaide, Queen Elizabeth Hosp, Adelaide, SA, Australia

[2] Heidelberg Repatriat Hosp, Olivia Newton John Canc & Wellness Ctr, Heidelberg, Australia

[3] Flinders Univ S Australia, Flinders Med Ctr, Adelaide, SA, Australia

[4] Flinders Univ S Australia, Flinders Ctr Innovat Canc, Adelaide, SA, Australia

[5] Royal Adelaide Hosp, Adelaide, SA, Australia

[6] Univ Adelaide, Lyell McEwin Hosp, Adelaide, SA, Australia

[7] Queen Elizabeth Hosp, Adelaide, SA, Australia

来源：

关键词：

D O I：

10.1200/JCO.2017.35.4_suppl.643

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

643

引用

页数：1